Insulet (PODD) Stock Forecast, Price & News

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PODD shares.
View PODD analyst ratings or view top-rated stocks.

16 analysts have issued twelve-month price objectives for Insulet's stock. Their PODD share price forecasts range from $185.00 to $350.00. On average, they predict the company's stock price to reach $280.40 in the next year. This suggests a possible upside of 76.1% from the stock's current price.
View analysts price targets for PODD or view top-rated stocks among Wall Street analysts.

Insulet's stock was trading at $294.39 at the beginning of 2023. Since then, PODD shares have decreased by 45.9% and is now trading at $159.22.
View the best growth stocks for 2023 here.

Insulet saw a decrease in short interest in September. As of September 15th, there was short interest totaling 2,880,000 shares, a decrease of 13.5% from the August 31st total of 3,330,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is presently 2.8 days.
View Insulet's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PODD earnings forecast.

Insulet will be holding an earnings conference call on Thursday, November 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Insulet Co. (NASDAQ:PODD) announced its earnings results on Tuesday, August, 8th. The medical instruments supplier reported $0.38 EPS for the quarter, beating the consensus estimate of $0.24 by $0.14. The medical instruments supplier had revenue of $396.50 million for the quarter, compared to analysts' expectations of $383.97 million. Insulet had a trailing twelve-month return on equity of 22.42% and a net margin of 4.29%.

ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Focused Discovery Growth ETF (IVDG), Harbor Health Care ETF (MEDI), Fidelity Disruptive Medicine ETF (FMED), VictoryShares Nasdaq Next 50 ETF (QQQN) and Nuveen ESG Mid-Cap Growth ETF (NUMG).

Insulet issued an update on its third quarter 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $402.14 million-$412.37 million, compared to the consensus revenue estimate of $400.90 million.

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PODD stock can currently be purchased for approximately $159.22.

Insulet (NASDAQ:PODD) has a market capitalization of $11.12 billion and generates $1.31 billion in revenue each year. The medical instruments supplier earns $4.60 million in net income (profit) each year or $0.89 on an earnings per share basis.

The company employs 2,600 workers across the globe.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.